Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD Study
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Annovis Bio (NYSE: ANVS) received a second consecutive positive independent safety-board recommendation for its Phase 3 DUET-AD trial in early Alzheimer’s disease.
The Data and Safety Monitoring Board recommended continuing without modification after its 12-month review. It assessed safety data accumulated through September 22, 2026, from 861 patients at different stages of dosing. This follows positive 6-month feedback announced in February 2026.
The trial evaluates buntanetap, an investigational once-daily pill. Annovis expects the last patient’s last visit for the 6-month treatment period on December 31, 2026, database lock on February 8, 2027, and 6-month topline results in March 2027, with detailed safety outcomes alongside symptomatic results. The company is also preparing for regulatory submission.
Positive
- Minor pointSecond consecutive positive safety-board recommendation supports continuing DUET-AD without modification after review of 861 patients’ safety data.
- Minor point. Forward-looking: it has not happened yet and may not happen.Six-month topline results remain expected in March 2027, alongside detailed safety outcomes.
- Minor pointRegulatory submission preparations are underway at Annovis.
Negative
- None.
Key Figures
- Patients reviewed
- 861 patients
- Safety data accumulated through September 22, 2026
- Review period
- 12 months
- Second DSMB review of DUET-AD
- Last patient, last visit
- December 31, 2026
- Expected end of the 6-month treatment period
- Database lock
- February 8, 2027
- DUET-AD
- 6-month topline results
- March 2027
- DUET-AD
Previous Clinical trial Reports
-
DSMB recommended the Phase 3 Alzheimer’s trial continue without modification after its six-month safety review.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
dsmb medical
database lock technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MALVERN, Pa., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing buntanetap, an investigational once-daily pill for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced an independent Data and Safety Monitoring Board (DSMB) has issued its second consecutive positive recommendation for DUET-AD, the Company’s pivotal Phase 3 trial in early AD, after the review of the study’s safety data. This 12-month review follows the DSMB’s positive 6-month feedback, which was announced in February 2026.
The DSMB recommended that DUET-AD continue without modification, based on the data accumulated through September 22, 2026, from 861 patients at different stages of dosing.
“A second positive recommendation from the DSMB in such a large population further reinforces our confidence in buntanetap’s safety profile,” said Cheng Fang, Ph.D., Chief Scientific Officer at Annovis. “This milestone comes at an important time. As we approach the 6-month data readout and prepare for regulatory submission, a demonstrated safety at scale is essential. In March, we will report detailed DUET-AD safety outcomes alongside the 6-month symptomatic results.”
DUET-AD (NCT06709014) remains on track, with last patient, last visit for the 6-month treatment period expected on December 31, 2026, database lock on February 8, 2027, and 6-month topline results in March 2027.
About Annovis
Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.
Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.
Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did the safety board recommend for Annovis Bio’s DUET-AD trial?
The independent Data and Safety Monitoring Board recommended that DUET-AD continue without modification. Its 12-month review covered safety data accumulated through September 22, 2026, from 861 patients at different stages of dosing. This was its second consecutive positive recommendation.
When does Annovis Bio expect DUET-AD six-month results?
Annovis expects 6-month topline results in March 2027, with detailed safety outcomes alongside symptomatic results. The last patient’s last visit for the 6-month treatment period is expected on December 31, 2026, followed by database lock on February 8, 2027.